ANI Pharmaceuticals, Inc.ANIPNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-25.59%
↓ 169% below average
Average (39q)
37.08%
Historical baseline
Range
High:1098.52%
Low:-87.03%
CAGR
+0.8%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -25.59% |
| Q2 2025 | 56.52% |
| Q1 2025 | -36.54% |
| Q4 2024 | 64.36% |
| Q3 2024 | 38.82% |
| Q2 2024 | -30.59% |
| Q1 2024 | 6.53% |
| Q4 2023 | -11.28% |
| Q3 2023 | 50.81% |
| Q2 2023 | 24.48% |
| Q1 2023 | 13.44% |
| Q4 2022 | -31.80% |
| Q3 2022 | 83.84% |
| Q2 2022 | -21.03% |
| Q1 2022 | 67.96% |
| Q4 2021 | 27.85% |
| Q3 2021 | -12.44% |
| Q2 2021 | -5.49% |
| Q1 2021 | -19.41% |
| Q4 2020 | 25.31% |
| Q3 2020 | -3.16% |
| Q2 2020 | -52.16% |
| Q1 2020 | 35.61% |
| Q4 2019 | -6.10% |
| Q3 2019 | -13.70% |
| Q2 2019 | 32.01% |
| Q1 2019 | 25.59% |
| Q4 2018 | -25.39% |
| Q3 2018 | -9.15% |
| Q2 2018 | 144.39% |
| Q1 2018 | -20.71% |
| Q4 2017 | 0.65% |
| Q3 2017 | 21.55% |
| Q2 2017 | 33.93% |
| Q1 2017 | 1098.52% |
| Q4 2016 | -87.03% |
| Q3 2016 | 36.26% |
| Q2 2016 | -20.91% |
| Q1 2016 | 46.14% |
| Q4 2015 | -18.90% |